VV-ECMO for ARDS after EOLIA… · 2019. 11. 22. · •Prone position, HFO ventilation, almitrine...
Transcript of VV-ECMO for ARDS after EOLIA… · 2019. 11. 22. · •Prone position, HFO ventilation, almitrine...
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
VV-ECMO for ARDS after EOLIA…Alain Combes, MD, PhD
Cardiology Institute, Hôpital Pitié-Salpêtrière, AP-HP
Inserm UMRS 1166, iCAN, Institute of Cardiometabolism and Nutrition
Sorbonne Université, Paris, [email protected]
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Disclosures• Principal Investigator: EOLIA trial
• VV ECMO in ARDS• NCT01470703 • Partly sponsored by MAQUET, Getinge Group
• Received honoraria for lectures and consulting from • MAQUET, BAXTER, XENIOS
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
The rationale ofhigh flow VV-ECMO…To completely replace pulmonary functionIn patients dying of refractory hypoxemia… ORFor whom MV becomes dangerous…
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Influenza A H1N1 induced ARDS
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
The rationale ofhigh flow VV-ECMO…To decrease the intensity of MV to protect the lungs
To allow the lungs to rest…To allow healing of the lungs…
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Potential Physiologic Mechanisms of Benefit of ECLS for Respiratory Failure
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Why early ECMO?To rapidly decrease the intensity of MV
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
0
0.2
0.4
0.6
0.8
1
0 20 40 60 80 100 120 140 160 180
MV 3-10 days before ECMO
MV >10 days before ECMO
P <0.005, log-rank
MV <3 days before ECMO
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
10
15
20
25
30
20
25
30
35
40
0
100
200
300
400
500Before ECMO After ECMO
0 0
Driving Pressure Tidal Volume Plateau Pressure
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Mechanical Power Concept• Energy transferred to the lungs/alveoli
• Components• Tidal volume (TV)/driving pressure (ΔPaw)
• Flow
• Positive end-expiratory pressure (PEEP)
• Respiratory rate (RR)
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Serpa Neto et al, Intensive Care Medicine, 2018
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Mechanical Power, J/min
LifeGuard, A Cohort of 350 patients on VV-ECMOSchmidt et al, AJRCCM 19
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
VV-ECMO indicationsafter EOLIA…
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Trial Procedures
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Trial proceduresECMO Group• Percutaneous VV Cannulation
• Low anticoag. with Heparin• aPTT 40–55 seconds
• MV settings• VAC
• PEEP ≥10, VT set for Pplat ≤24 cmH2O
• Pressure controlled/APRV• PLow ≥10; PHigh ≤24 cmH2O; I:E, 1/2
• FIO2 30-50%, RR 10–30
Control Group• MV settings
• Express trial; High recruitment arm • VT at 6 ml/kg• PEEP to reach Pplat 28–30 cm H2O
• Strong recommendation for• Prolonged periods of prone position• Paralyzing agents
• In case of hypoxemia• Recruitment maneuvers • iNO, inhaled prostacyclin
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Rescue ECMO for Controls• Refractory hypoxemia
• SaO2 <80% for >6 hours
• Despite mandatory trial of• Prone positioning AND
• Recruitment maneuver AND
• iNO or inhaled prostacyclin
• AND If the treating physician felt that• Patient had no irreversible multi-organ failure AND
• ECMO might change the outcome
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Primary Endpoint
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Hazard Ratio, 0.70; 95% CI, 0.47-1.04, P=0.074 by log-rank test
0
5
10
15
20
25
30
35
40
45
50
ECMO Control
35 46
Perc
ent
D6
0 M
ort
alit
yPrimary EndpointRelative Risk, 0.76, 95% Cl, 0.55-1.04; P=0.087
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Key Secondary EndpointDeath in ECMO group patients
Death or Crossover to ECMO in controls
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Hazard ratio, 0.48; 95% CI, 0.34-0.70, P <0.001 by log-rank test
0
10
20
30
40
50
60
ECMO Control
35
57
Perc
ent
D6
0 T
reat
men
tFa
ilure
Key Secondary EndpointRelative Risk, 0.62; 95% CI, 0.47-0.82; P<0.001
Death in ECMO group patients; Death or Crossover to ECMO in control patientsPe
rcen
t D
60
Tre
atm
ent
Failu
re
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Crossover to ECMO
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Crossover to ECMO in Controls• 28% (35/125) of controls received rescue ECMO
• Refractory hypoxemia, 6.5±9.7 days postrandomization
• These patients had more severe ARDS at baseline• Higher Plateau pressure:
• 31.7±5.5 vs 28.5±4.1 cm H2O
• Higher Driving pressure: • 20.2±6.1 vs 16.6±5.3 cm H2O
• Lower Respiratory system compliance: • 21.3±9.2 vs 27.1±11.0 ml/cm H2O
• More quadrants with infiltrate on chest Xray: • 3.7±0.6 vs 3.3±0.9
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
H-24-18 H-18-12 H-12-6 H-6-3 H-3-0 H-24-18 H-18-12 H-12-6 H-6-3 H-3-0
H-24-18 H-18-12 H-12-6 H-6-3 H-3-0 H-24-18 H-18-12 H-12-6 H-6-3 H-3-0
Inotropic Score, P < 0.001 Pao2, P < 0.001
Arterial lactate, P < 0.001 Pao2:Fio2, P < 0.001
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Crossover to ECMO in Controls• Before crossover, of the 35 controls who had ECMO
• 9 had cardiac arrest
• 7 had severe right heart failure
• 11 developed renal failure requiring dialysis
• Venoarterial ECMO applied to 7 patients• 6 under cardiopulmonary resuscitation
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
0
10
20
30
40
50
60
ECMO No Crossover All Controls Crossover
3541
4657
Perc
en
t M
ort
alit
y
Control Crossover Outcomes
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Matching weight ponderation:Rescue ECMO (35) vs. First line ECMOSimilar baseline severity
Mortality: Rescue ECMO 57% vs. First line ECMO 35%Hazard ratio, 1,64; 95% CI, 1,08-2.49
P = 0.02
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Subgroups…
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Which patients should receive ECMO?
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Which patients should receive ECMO?
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Inclusion Criteria• One of the 3 following disease severity criteria
• PaO2:FIO2 <50 mmHg for >3 hours• Despite potential use of inhaled NO, recruitment maneuvers
• Prone position, HFO ventilation, almitrine infusion
• PaO2:FIO2 <80 mmHg for >6 hours• Despite similar criteria as above
• pH <7.25 with PaCO2 >60 mmHg for >6 hours • Resulting from MV settings to keep Pplat ≤32 cm H2O
• Despite respiratory rate increased to 35/minute
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Endpoint
ECMO group
(N = 124)
Control group
(N = 125)
Absolute Risk
Difference or Median
Difference (95% CI)
Day 60 mortality by inclusion criteria
Criteria #1 — no. died/ total no. (%) 1/5 (20) 1/11 (9) 10.9 (-25.0 to 56.9)
Criteria #2 — no. died/ total no. (%) 37/94 (39) 45/94 (48) -8.5 (-22.4 to 5.7)
Criteria #3 — no. died/ total no. (%) 6/25 (24) 11/20 (55) -31.0 (-55.7 to -2.2)
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Bayesian Model
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
JAMA. October 22, 2018, doi:10.1001/jama.2018.14276
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Bayesian Analysis of EOLIA…
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Bayesian Analysis of EOLIA…Dead space and static compliance determine the effect of ECCO2R
on driving pressure and mechanical power
Posterior Probability of Positive Effect of ECMO in
Severe ARDS Patients88% to 99%
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Clinicians and researchers should no longer ask
“Does ECMO work?” because that question appears to be
answered...
Instead, the key question that should now be asked is “By
how much does ECMO work, in whom, and at what cost?”
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
And now the Meta-Analyses…
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Lancet Resp Med, 2019
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Lancet Resp Med, 2019
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
Conclusions• ECMO does not kill people!• ECMO is very likely of benefit to patients with severe ARDS
• All patients should receive Prone prior to ECMO• Unclear at present which patients will benefit the most
• Driving pressure? Mechanical Power?
• Further studies are needed:• Which patients• Optimal ventilatory strategy during ECMO
• +/- prone during ECMO• Optimal coagulation regimen• ECMO vs ECCO2R
La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]
www.paris-ecostcs.com